IMGN853 (MIRV, Мирветуксимаб соравтанзин)
Проводит ИммуноГен, Инк.
Страница компанииMIRASOL: рандомизированное открытое исследование фазы 3 для сравнения мирветуксимаба соравтанзина и химиотерапевтического препарата на выбор исследователя при прогрессирующем высокозлокачественном эпителиальном раке яичника, первичном раке брюшины или раке фаллопиевой трубы, резистентным к препаратам платины, с высоким уровнем экспрессии рецептора фолиевой кислоты альфа
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/297/2020-06-26/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 80 чел. в стране «Россия».
- Центров в реестре: 7 в 7 городах. Список — ниже на странице.
- Плановая дата окончания (09.2023) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Состояние пациента (ECOG)0–1
- Опухольнужен измеримый очаг (RECIST)
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 31 · невключение: 30
Критерии включения
- Female participants ≥ 18 years of age
- Participants must have a confirmed diagnosis of high-grade serious epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- Participants must have platinum-resistant disease:
- Participants who have only had 1 line of platinum based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between >3 months and ≤ 6 months after the date of the last dose of platinum
- Participants who have received 2 or 3 lines of platinum therapy must have progressed on or within 6 months after the date of the last dose of platinum Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression. Note: Participants who are platinum-refractory during front-line treatment are excluded
- Participants must have progressed radiographically on or after their most recent line of therapy
- Participants must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low risk, medically routine procedure for immunohistochemistry (IHC) confirmation of FRα positivity
- Participant's tumor must be positive for FRα expression as defined by the Ventana FOLR1 (FOLR-2.1) CDx assay
- Participants must have at least one lesion that meets the definition of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (radiologically measured by the Investigator)
- Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment:
- Adjuvant ± neoadjuvant considered one line of therapy
- Maintenance therapy (for example, bevacizumab, poly (ADP-ribose) polymerase \[PARP\] inhibitors) will be considered as part of the preceding line of therapy (that is, not counted independently)
- Therapy changed due to toxicity in the absence of progression will be considered as part of the same line (that is, not counted independently)
- Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance
- Participant must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- Time from prior therapy:
- Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter)
- Focal radiation completed at least 2 weeks prior to first dose of study drug
- Participants must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities
- Major surgery must be completed at least 4 weeks prior to first dose and have recovered or stabilized from the side effects of prior surgery
- Participants must have adequate hematologic, liver and kidney functions defined as:
- Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/liter (L) (1,500/microliter \[μL\]) without granulocyte colony-stimulating factor (G-CSF) in the prior 10 days or long-acting white blood cell (WBC) growth factors in the prior 20 days
- Platelet count ≥ 100 x 10\^9/L (100,000/μL) without platelet transfusion in the prior 10 days
- Hemoglobin ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days
- Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN
- Serum bilirubin ≤ 1.5 x ULN (participants with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 x ULN
- Serum albumin ≥ 2 grams (g)/deciliter (dL)
- Participants or their legally authorized representative must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements
- Women of childbearing potential (WCBP) must agree to use highly effective contraceptive method(s) while on study drug and for at least 3 months after the last dose of MIRV or at least 6 months after the last dose of paclitaxel, pegylated liposomal doxorubicin, or topotecan
- WCBP must have a negative pregnancy test within 4 days prior to the first dose of study drug
Критерии невключения
- Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade or borderline ovarian tumor
- Participants with primary platinum-refractory disease, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of first line platinum-containing chemotherapy
- Participants with prior wide-field radiotherapy (RT) affecting at least 20% of the bone marrow
- Participants with > Grade 1 peripheral neuropathy per Common Terminology Criteria for Adverse Events (CTCAE) v5.0
- Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision
- Participants with serious concurrent illness or clinically relevant active infection, including, but not limited to the following:
- Active hepatitis B or C infection (whether or not on active antiviral therapy)
- Human immunodeficiency virus (HIV) infection
- Active cytomegalovirus infection
- Any other concurrent infectious disease requiring IV antibiotics within 2 weeks before starting study drug Note: Testing at screening is not required for the above infections unless clinically indicated
- Participants with history of multiple sclerosis or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)
- Participants with clinically significant cardiac disease including, but not limited to, any one of the following:
- Myocardial infarction ≤ 6 months prior to first dose
- Unstable angina pectoris
- Uncontrolled congestive heart failure (New York Heart Association > class II)
- Uncontrolled ≥ Grade 3 hypertension (per CTCAE)
- Uncontrolled cardiac arrhythmias
- Participants assigned to PLD stratum only: Left ventricular ejection fraction (LVEF) below the institutional limit of normal as measured by echocardiography (ECHO) or multigated acquisition (MUGA) scan
- Participants with a history of hemorrhagic or ischemic stroke within six months prior to randomization
- Participants with a history of cirrhotic liver disease (Child-Pugh Class B or C)
- Participants with a previous clinical diagnosis of non-infectious interstitial lung disease (ILD), including noninfectious pneumonitis
- Participants with required use of folate-containing supplements (for example, folate deficiency)
- Participants with prior hypersensitivity to monoclonal antibodies
- Women who are pregnant or lactating
- Participants with prior treatment with MIRV or other FRα-targeting agents
- Participants with untreated or symptomatic central nervous system (CNS) metastases
- Participants with a history of other malignancy within 3 years prior to randomization. Note: does not include tumors with a negligible risk for metastasis or death (for example, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
- Prior known hypersensitivity reactions to study drugs and/or any of their excipients
- People who are detained through a court or administrative decision, receiving psychiatric care against their will, adults who are the subject of a legal protection order (under tutorship/curatorship), people who are unable to express their consent, and people who are subject to a legal guardianship order
- Simultaneous participation in another research study, in countries or localities where this is the health authority guidance
Источник: ClinicalTrials.gov, NCT04209855 · запись обновлена в реестре 27 августа 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 7
- Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — From randomization until PD or death, whichever occurred first (up to approximately 36 months)
Цель исследования
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. The FRα positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.
Области и заболевания
Где проходит
7 центров в 7 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 297 от 26.06.2020 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04209855 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.